Zynerba Pharmaceuticals Inc. (ZYNE)

6.14
0.08 1.30
NASDAQ : Health Technology
Prev Close 6.22
Open 6.36
Day Low/High 5.46 / 6.40
52 Wk Low/High 2.75 / 12.50
Volume 1.93M
Avg Volume 926.50K
Exchange NASDAQ
Shares Outstanding 21.07M
Market Cap 117.36M
EPS -2.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

The Action in Select Small Caps Is Encouraging

The Action in Select Small Caps Is Encouraging

It's tough to do much while we await major news events.

SCYNEXIS Announces Appointment Of Industry Veteran Armando Anido To Its Board Of Directors

SCYNEXIS Announces Appointment Of Industry Veteran Armando Anido To Its Board Of Directors

Brings executive, operational, business development and commercial leadership expertise based on over 30 years in the biopharmaceutical industry

First Week Of December 21st Options Trading For Zynerba Pharmaceuticals (ZYNE)

First Week Of December 21st Options Trading For Zynerba Pharmaceuticals (ZYNE)

Investors in Zynerba Pharmaceuticals Inc saw new options begin trading this week, for the December 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZYNE options chain for the new December 21st contracts and identified one put and one call contract of particular interest.

Insiders Find Value In These 3 Small Caps

Insiders Find Value In These 3 Small Caps

This sort of insider activity often coincides with a turnaround in these types of beaten down equities.

Insys Therapeutics Is a Pretend Cannabis Stock

Insys Therapeutics Is a Pretend Cannabis Stock

It is time for investors to start differentiating between the Good, the Bad and the Ugly in cannabis stocks.

FDA Approval Of GW Pharma's Cannabis-Based Drug Marks Milestone

FDA Approval Of GW Pharma's Cannabis-Based Drug Marks Milestone

Approval of epilepsy drug using the marijuana derivative CBD is the first time the FDA has sanctioned medical use of cannabidiol.

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

FDA Approval Puts GW Pharma, Three Other Cannabis-Related Names in the Spotlight

The milestone approval of Epidiolex bodes well for cannabis-based drug stocks GW Pharma, Nemus, Zynerba and Insys.

Interesting ZYNE Put And Call Options For November 16th

Investors in Zynerba Pharmaceuticals Inc saw new options begin trading this week, for the November 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 210 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Zynerba Pharmaceuticals Becomes Oversold (ZYNE)

Zynerba Pharmaceuticals Becomes Oversold (ZYNE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Zynerba Pharmaceuticals Announces Publication Of Preclinical Data In Neuropsychopharmacology Demonstrating Effect Of Cannabidiol Gel Treatment In Reduction Of Relapse In An Addiction Model

Zynerba Pharmaceuticals Announces Publication Of Preclinical Data In Neuropsychopharmacology Demonstrating Effect Of Cannabidiol Gel Treatment In Reduction Of Relapse In An Addiction Model

Results show effect of transdermally-delivered cannabidiol (ZYN002) in an animal model of drug relapse and extend its therapeutic potential to relapse prevention in substance use disorders

Oversold Conditions For Zynerba Pharmaceuticals (ZYNE)

Oversold Conditions For Zynerba Pharmaceuticals (ZYNE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

My Buy-Write Strategy Amid Market Swings

My Buy-Write Strategy Amid Market Swings

It's a simple option strategy to mitigate some risk in deploying new funds.

Zynerba Pharmaceuticals Reaches Analyst Target Price

Zynerba Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Zynerba Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $13.00, changing hands for $13.45/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Short Interest In Zynerba Pharmaceuticals Moves 27.4% Higher

Short Interest In Zynerba Pharmaceuticals Moves 27.4% Higher

The most recent short interest data has been released for the 10/13/2017 settlement date, which shows a 609,213 share increase in total short interest for Zynerba Pharmaceuticals Inc , to 2,836,313, an increase of 27.35% since 09/29/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Zynerba Pharmaceuticals Reaches Analyst Target Price

Zynerba Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Zynerba Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $8.14, changing hands for $9.44/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Notable Thursday Option Activity: ZYNE, EPC, RDI

Notable Thursday Option Activity: ZYNE, EPC, RDI

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Zynerba Pharmaceuticals Inc , where a total of 12,054 contracts have traded so far, representing approximately 1.2 million underlying shares. That amounts to about 361.3% of ZYNE's average daily trading volume over the past month of 333,605 shares.

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.